, Tracking Stock Market Picks
Enter Symbol:
Adolor Corporation (ADLR) [hlAlert]

up 188.96 %

Adolor Corporation (ADLR) downgraded to Hold by Brean Murray

Posted on: Monday,  Oct 24, 2011  12:25 PM ET by Brean Murray

Brean Murray rated Hold Adolor Corporation (NASDAQ: ADLR) on 10/24/2011. Previously Brean Murray rated Buy Adolor Corporation (NASDAQ: ADLR) on 06/15/2011.,
when the stock price was $1.54. Since then, Adolor Corporation has gained 188.96% as of 10/24/2011's recent price of $4.45.
If you would have followed the previous Brean Murray's recommendation on ADLR, you would have gained 188.96% of your investment in 131 days.

Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company?s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2011 12:25 PM Hold
as of 12/30/2011
1 Week   
1 Month   
3 Months up  158.72 %
1 YTD up  267.76 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/15/2011 12:25 PM Buy
1.54 5.00
5/31/2011 9:25 AM Buy
1.55 4.00
6/18/2010 8:25 AM Buy
1.23 3.00
7/14/2009 8:25 AM Buy
1.75 4.00
4/29/2009 2:25 PM Buy
2.30 4.00
9/8/2008 8:25 AM Buy
3.38 6.00
8/6/2008 9:25 AM Hold
3/12/2008 1:25 PM Buy
4.69 9.00
9/12/2007 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy